LYON, France--(BUSINESS WIRE)--Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies ...
13d
Sedana Medical AB: Sedana Medical reports first patient treated in Early Access Program in the U.S.
Sedana Medical AB (publ) today reports that the first patient has been treated in the company's Early Access Program (EAP) in the U.S. The program is approved by the U.S. Food and Drug Administration ...
Nautilus debuted its platform at the US HUPO meeting last month and is seeking additional participants for its ongoing early ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results